GSA Capital Partners LLP boosted its stake in shares of AtriCure Inc. (NASDAQ:ATRC) by 135.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 26,054 shares of the medical device company’s stock after purchasing an additional 14,984 shares during the quarter. GSA Capital Partners LLP’s holdings in AtriCure were worth $705,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Trexquant Investment LP bought a new position in AtriCure in the 1st quarter worth about $224,000. JPMorgan Chase & Co. increased its stake in AtriCure by 105.1% in the 1st quarter. JPMorgan Chase & Co. now owns 14,208 shares of the medical device company’s stock worth $292,000 after acquiring an additional 7,281 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in AtriCure by 481.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 263,831 shares of the medical device company’s stock worth $5,414,000 after acquiring an additional 218,485 shares during the last quarter. First Light Asset Management LLC increased its stake in AtriCure by 8.6% in the 1st quarter. First Light Asset Management LLC now owns 1,167,672 shares of the medical device company’s stock worth $23,961,000 after acquiring an additional 92,225 shares during the last quarter. Finally, Millennium Management LLC increased its stake in AtriCure by 13.6% in the 1st quarter. Millennium Management LLC now owns 859,871 shares of the medical device company’s stock worth $17,645,000 after acquiring an additional 102,911 shares during the last quarter. Institutional investors own 90.78% of the company’s stock.

Shares of AtriCure stock opened at $33.93 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.37 and a current ratio of 3.16. AtriCure Inc. has a 12 month low of $14.88 and a 12 month high of $35.17.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Wednesday, August 1st. The medical device company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.04. The firm had revenue of $51.80 million for the quarter, compared to analyst estimates of $49.94 million. AtriCure had a negative return on equity of 16.57% and a negative net margin of 10.85%. The company’s revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.21) EPS. equities research analysts expect that AtriCure Inc. will post -0.89 earnings per share for the current year.

A number of equities analysts have weighed in on the company. Zacks Investment Research upgraded AtriCure from a “sell” rating to a “hold” rating in a research note on Friday, August 24th. ValuEngine upgraded AtriCure from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 3rd. Stifel Nicolaus upped their target price on AtriCure from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. BTIG Research restated a “hold” rating on shares of AtriCure in a research note on Thursday, August 2nd. Finally, Canaccord Genuity restated a “buy” rating and issued a $37.00 target price on shares of AtriCure in a research note on Thursday, August 2nd. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $32.40.

In other news, SVP Justin J. Noznesky sold 4,000 shares of the stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $30.32, for a total transaction of $121,280.00. Following the transaction, the senior vice president now directly owns 124,920 shares in the company, valued at approximately $3,787,574.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

About AtriCure

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Featured Article: Fundamental Analysis and Choosing Stocks

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.